Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers-Reference-Cited by-同舟云学术

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

Published:2020-11 Issue:11 Volume:42 Page:2171-2183.e4
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Nakamura Tadakatsu,Shimizu Hidetoshi,Kawaguchi Atsuhiro

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology;Cannavo;Oxid Med Cell Longev,2018

2. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation;Ishizawa;Hypertension,2005

3. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability;Nishiyama;Hypertension,2005

4. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure;Capelli;J Nephrol,2020

5. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease;Dojki;Curr Opin Nephrol Hypertens,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes;Current Cardiology Reports;2023-11-22

2. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy;Hypertension Research;2022-06-20

3. Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist;Journal of Medicinal Chemistry;2022-06-02

4. Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease;British Journal of Pharmacology;2022-01-13

5. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study;Hepatology Research;2021-08-05